265 related articles for article (PubMed ID: 37112915)
1. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
[TBL] [Abstract][Full Text] [Related]
4. Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
Schneider S; Blick G; Burke C; Ward D; Benson P; Felizarta F; Green D; Donovan C; Harper G; Merrill D; Metzner AA; Mycock K; Wallis H; Patarroyo J; Brogan AP; Oglesby A
Infect Dis Ther; 2024 Apr; 13(4):891-906. PubMed ID: 38570443
[TBL] [Abstract][Full Text] [Related]
5. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
6. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Cento V; Perno CF
J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
Punekar YS; Parks D; Joshi M; Kaur S; Evitt L; Chounta V; Radford M; Jha D; Ferrante S; Sharma S; Van Wyk J; de Ruiter A
HIV Med; 2021 Jul; 22(6):423-433. PubMed ID: 33529489
[TBL] [Abstract][Full Text] [Related]
8. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
[TBL] [Abstract][Full Text] [Related]
9. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
Hidalgo-Tenorio C; Vinuesa D; García-Vallecillos C; Muñoz-Medina L; Sequera S; Javier R; López-Ruz MÁ; Sadyrbaeva-Dolgova S; Pasquau J
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560630
[TBL] [Abstract][Full Text] [Related]
10. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
12. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
[TBL] [Abstract][Full Text] [Related]
13. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Troya J; Dueñas C; Irazola I; de Los Santos I; de la Fuente S; Gil D; Hernández C; Galindo MJ; Gómez J; Delgado E; Moreno-García E; Pousada G; Aldámiz T; Iribarren JA; Guerra JM; Morán MÁ; Galera C; De La Fuente J; Peláez A; Cervero M; Garcinuño M; Montero M; Ceballos F; Buzón L;
Medicine (Baltimore); 2022 Jun; 101(24):e29252. PubMed ID: 35713430
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
[No Abstract] [Full Text] [Related]
16. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients.
Revuelta-Herrero JL; Chamorro-de-Vega E; Rodríguez-González CG; Alonso R; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2018 Jan; 52(1):11-18. PubMed ID: 28836468
[TBL] [Abstract][Full Text] [Related]
17. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
Teira R; Diaz-Cuervo H; Aragão F; Castaño M; Romero A; Roca B; Montero M; Galindo MJ; Muñoz-Sánchez MJ; Espinosa N; Peraire J; Martínez E; de la Fuente B; Domingo P; Deig E; Merino MD; Geijo P; Estrada V; Sepúlveda MA; García J; Berenguer J; Currán A
Infect Dis Ther; 2022 Jun; 11(3):1177-1192. PubMed ID: 35399147
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
Lim ZC; Hoo GS; Ang JH; Teng CB; Ang LW; Lee CC; Leo YS; Law HL; Ng OT; Wong CS
AIDS Res Ther; 2021 Nov; 18(1):80. PubMed ID: 34724931
[TBL] [Abstract][Full Text] [Related]
19. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid.
Amor-García MÁ; Rodríguez-González CG; Chamorro-de-Vega E; Herranz-Alonso A; Sanjurjo-Sáez M
Ann Pharmacother; 2022 Apr; 56(4):401-411. PubMed ID: 34382435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
